The cells were fixed with 4% paraformaldehyde for 15 min and then blocked with phosphate-buffered saline (PBS) containing 2% fetal bovine serum, 2%
bovine serum albumin, and 0.1%
Triton X-100 (Wako Pure Chemicals Industries, Osaka, Japan) for 1 h. Then, the cells were incubated with a primary antibody at 4°C overnight, followed by incubation with a secondary antibody at room temperature for 1 h.
The protein extracts were submitted to western blot analysis using a standard protocol.
The following primary antibodies were used: mouse anti-KIF20A antibody (Santa Cruz Biotechnologies, Dallas, TX),
anti-cleaved caspase-3 (Santa Cruz Biotechnologies), anti-Bax (Cell Signaling Techology, Danvers, MA),
anti-Bcl-2 (Cell Signaling Technology), anti-phospho-JAK2 (Cell Signaling Technolgoy),
anti-JAK2 (Cell Signaling Technology),
anti-phospho-STAT3 (Cell Signaling Technology), and
anti-STAT3 (Cell Signaling Technology). A
mouse anti-β-actin monoclonal antibody (Cell Signaling Technology) was used as a loading control.
Xiong M., Zhuang K., Luo Y., Lai Q., Luo X., Fang Y., Zhang Y., Li A, & Liu S. (2019). KIF20A promotes cellular malignant behavior and enhances resistance to chemotherapy in colorectal cancer through regulation of the JAK/STAT3 signaling pathway. Aging (Albany NY), 11(24), 11905-11921.